Breaking News
Investing Pro 0
🙌 It's Here: the Only Stock Screener You'll Ever Need Get Started
Close

AstraZeneca PLC ADR (AZN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow AstraZeneca ADR's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
72.59 -0.25    -0.34%
02/06 - Closed. Currency in USD ( Disclaimer )
After Hours
72.65
+0.06
+0.08%
19:51:25 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 8,038,949
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 72.57 - 73.42
AstraZeneca ADR 72.59 -0.25 -0.34%

NASDAQ:AZN Financials

 
A brief overview of the NASDAQ:AZN financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Astrazeneca over time.

AstraZeneca PLC reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 286 million compared to USD 152 million a year ago. Revenue was USD 10,879 million compared to USD 11,390 million a year ago. Net income was USD 1,803 million compared to USD 386 million a year ago. Basic earnings per share from continuing operations was USD 1.16 compared to USD 0.25 a year ago. Diluted earnings per share from continuing operations was USD 1.16 compared to USD 0.25 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

AZN Income Statement

Gross margin TTM 84.3%
Operating margin TTM 23.1%
Net Profit margin TTM 10.73%
Return on Investment TTM 11.79%
 Total Revenue  Net Income
Period Ending: Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022
Total Revenue 10879 11207 10982 10771
Gross Profit 9106 8737 8941 8942
Operating Income 2687 1668 2282 2021
Net Income 1803 901 1640 360

AZN Balance Sheet

Quick Ratio MRQ 0.67
Current Ratio MRQ 0.9
LT Debt to Equity MRQ 75.58%
Total Debt to Equity MRQ 90.73%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022
Total Assets 96687 96483 94185 96579
Total Liabilities 60876 59425 59031 60628
Total Equity 35811 37058 35154 35951

AZN Cash Flow Statement

Cash Flow/Share TTM 6.26
Revenue/Share TTM 28.29
Operating Cash Flow  12.60%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 3133 2398 2930 1248
Cash From Investing Activities -1246 -249 -1743 -800
Cash From Financing Activities -2031 -358 -1430 -1295
Net Change in Cash -155 1797 -294 -873
* In Millions of (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AZN Comments

Write your thoughts about AstraZeneca PLC ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Andre Van Laer
Andre Van Laer Mar 23, 2023 2:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why would anyone buy this thing...?
Neek Kajula
Neek Kajula Mar 24, 2022 9:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
did they develop a vaccine that works now or why is thos going up?
Hold This Sheet
Hold This Sheet Sep 23, 2021 2:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Valneva
damian del
mudlog79 Sep 20, 2021 3:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why this trash going up?
Pascal Torres
Pascal Torres Sep 20, 2021 3:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
speculation
Trader Global
Trader Global Sep 03, 2021 12:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
already breakout guy.
Adrian Vanyi
Adrian Vanyi Aug 09, 2021 2:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I would await some further drop based on the below article to come in the near future. The company did not perform well with the vaccine and i opened some short positions if my assumptions are correct.
Adrian Vanyi
Adrian Vanyi Aug 09, 2021 2:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://moneyweek.com/investments/stocks-and-shares/biotech-stocks/603675/astrazenecas-covid-troubles-could-see-it-pull
ray ford
ray ford Jun 30, 2021 8:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hold long = big victory ✌
Leo Mu
Leo Mu Jun 28, 2021 3:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Finally it reached $60+.
Leo Mu
Leo Mu Jun 24, 2021 9:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
AZN and MRK: Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer. Support is strong for the 2 stocks.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email